Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cellular Origins of EGFR‐Driven Lung Cancer Cells Determine Sensitivity to Therapy

7 Oct 2021

Abstract excerpt

Targeting the epidermal growth factor receptor (EGFR) with tyrosine kinase inhibitors (TKIs) is one of the major precision medicine treatment options for lung adenocarcinoma. Due to common development of drug resistance to first- and second-generation TKIs, third-generation inhibitors, including osimertinib and rociletinib, have been developed. A model of EGFR-driven lung cancer and a method to develop tumors of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34622577
DOI: 10.1002/advs.202101999

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cellular Origins of EGFR‐Driven Lung Cancer Cells Determine Sensitivity to TherapyPMID 34622577Read ↗

Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung CancerSemantic proximity Read ↗

Lung Adenocarcinoma Tumor Origin: A Guide for Personalized MedicineSemantic proximity Read ↗

Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinomaSemantic proximity Read ↗

A novel mouse cell line model reveals the tumor intrinsic and immune characteristics of EGFR-mutant lung cancer.Semantic proximity Read ↗

Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiationSemantic proximity Read ↗

Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem CellsSemantic proximity Read ↗

Epigenetics of lung cancer: a translational perspectiveSemantic proximity Read ↗

Modeling diverse genetic subtypes of lung adenocarcinoma with a next-generation alveolar type 2 organoid platformSemantic proximity Read ↗

The Genomics of Lung Adenocarcinoma: Opportunities for Targeted TherapiesSemantic proximity Read ↗

Complementary modes of resistance to <i>EGFR</i> TKI in lung adenocarcinoma through MAPK activation and cellular plasticitySemantic proximity Read ↗

Epigenome-Based Precision Medicine in Lung Cancer.Semantic proximity Read ↗

Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.